CuraGen Sells Ownership of Belinostat to Topo... ( - CuraGen to receive approximately ...)

CuraGen Sells Ownership of Belinostat to TopoTarget A/S

Date:4/22/2008

- CuraGen to receive approximately $45 million in cash, stock and future

milestone payments -

- Provides updated financial guidance for 2008 -

- Conference call to be hosted today at 9:00 a.m. EDT -

BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company, announced today that it has sold its ownership in belinostat, a Phase I/II histone deacetylase inhibitor, to TopoTarget A/S (Copenhagen Stock Exchange: TOPO) for approximately $39 million upfront in a combination of cash and stock. CuraGen will receive $26 million in cash and 5 million shares of TopoTarget common stock, currently valued at approximately $13 million, and $6 million in potential commercial milestone payments related to future net sales and sublicenses of belinostat. CuraGen will no longer have any funding requirements for belinostat as TopoTarget will immediately assume all financial and operational responsibility for the ongoing clinical development.

"CuraGen is working to create and unlock value within our portfolio while providing a strong and clear risk / reward profile for our investors. After a thorough review of our current strategic options, we feel the most effective use of our resources and best potential value creation opportunity for shareholders is based on CR011-vcMMAE, our un-partnered antibody-drug conjugate, currently in Phase II for the treatment of patients with metastatic melanoma and moving toward Phase II in metastatic breast cancer. We believe that today's deal represents a great opportunity for CuraGen, and its shareholders, by further strengthening our balance sheet by adding close to $45 million this year
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
2. CuraGen Appoints Clinical Oncologist as VP of Medical Development
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. CuraGen Corporation Receives Notification from NASDAQ
7. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
8. CuraGen to Present at the BIO CEO & Investor Conference
9. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
10. Exelixis Sells 80% Stake in Artemis to Taconic
11. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates

Post Your Comments:

CuraGen Sells Ownership of Belinostat to Topo...( - CuraGen to receive approximately ...)